Navigation Links
Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
Date:6/23/2013

LONDON, June 24, 2013 /PRNewswire/ --

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia.  ST10 is a novel form of ferric iron taken orally.

Patients with inflammatory bowel disease and anaemia have been recruited and randomised when oral ferrous products have been ineffective due to intolerance and/or inadequate therapeutic benefit.  The primary endpoint of this pivotal international, multi-centre programme is haemoglobin change after 12 weeks' treatment with ST10 compared to placebo.  Subjects have been included from expert centres in Austria, Germany, Hungary and the UK and either randomised to receive 30mg of ST10 twice a day, or a matched placebo capsule.  Following the randomised treatment period there is an open-label phase that allows all patients to be treated with ST10 for an additional year.  Other iron therapies have not been permitted during the study.  

Shield Therapeutics expects to report top-line results from the study at the end of Q4 2013 and anticipates these results will provide confirmatory pivotal clinical data that may form the basis of an MAA submission to the European regulatory authorities in 2014.  The data is also expected to form part of a subsequent NDA submission in the USA.

Commenting on the study, Professor Gasche, Professor of Medicine, Medical University of Vienna, Austria said:

"Inflammatory bowel disease is one of the most prevalent diseases managed by gastroenterologists.  Approximately half of all IBD patients develop iron deficiency and that can readily progress to more severe anaemia, which is the leading cause of fatigue that debilitates day-to-day quality of life.  The oral ferrous iron preparations are often poorly tolerated, leaving intravenous iron infusions as the preferred option.  However these require significant additional patient time and healthcare resources, hence there is an urgent need for a more convenient solution which we anticipate ST10 may deliver."

Shield Founder and Chief Executive Officer, Carl Sterritt, added:

"We are very grateful to the patients for their commitment, as well as the investigators and their research staff for their hard work and considerable skill that has made this study possible.  The completion of recruitment into this pivotal trial is an important step in bringing orally dosed ST10 to market as an effective way of correcting anaemia in patients who cannot tolerate oral ferrous iron therapy and so have to rely on the higher risk option of invasive and resource-consuming intravenous administration of iron."

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need.  Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:
M:Communications
Mary-Jane Elliott / Sarah Macleod/ Hollie Vile
Tel +44(0)20-7920-2330
Email: shieldtherapeutics@mcomgroup.com



'/>"/>
SOURCE Shield Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ASSA ABLOY Door Group Announces RF Shielding Openings
2. Blue Cross Blue Shield Texas Launches "Be Covered Texas" Campaign to Raise Awareness of Individual Health Insurance Enrollment Options
3. Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017
4. Healthcare Fraud Shield Now Offers SIU Services
5. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
6. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
7. Shield HealthCare Announces 12th Annual Caregiver Story Contest
8. Wellness Center USA, Inc. Completes Psoria-Shield Inc. Acquisition
9. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
10. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
11. Blue Cross Blue Shield of Michigan and Blue Care Network support the Drug Enforcement Administrations Nationwide Prescription "Drug Take-Back Day"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... OAKLAND, Calif. , Feb. 11, 2016  Walgreens ... stores across 39 states and Washington, D.C. ... in a move that was commended by shareholder advocacy organization ... President at As You Sow. "Many people hold on to ... options, which can have tragic consequences." --> ...
(Date:2/11/2016)... 2016  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and other birth tissues, human skin and bone, and ... advanced products and therapies, announced today that it will ... Conference in New York , NY.  ... J. Senken , Chief Financial Officer and Chris ...
Breaking Medicine Technology:
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization ... a partnership with San Ramon Regional Medical Center. Under the collaboration, the first of ... way to accommodate a more certain time frame for donor families for the recovery ...
Breaking Medicine News(10 mins):